文献速递呼吸道感染呼吸危重症与机械通气

氢化可的松联合氟氢可的松治疗社区获得性肺炎相关脓毒性休克:APROCCHSS 3期随机试验亚组分析

Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial.
PubMed 文献 · Lancet Respir Med · 2024-02-01

该研究为APROCCHSS试验的预设探索性亚组分析,纳入1241例脓毒性休克患者,其中562例为社区获得性肺炎(CAP)。

要点

  • CAP相关脓毒性休克患者接受氢化可的松联合氟氢可的松可降低90天死亡率。
  • 非CAP相关脓毒性休克患者未见显著获益。

研究设计与样本

  • APROCCHSS为在法国34个中心进行的3期随机对照试验,采用2×2析因设计,后改为两组平行。
  • 本分析为预设探索性亚组分析,纳入1241例脓毒性休克患者,其中562例CAP,648例非CAP,31例无法判定。
  • 干预为7天氢化可的松50mg每6小时静脉推注联合氟氢可的松50μg鼻胃管给药,或安慰剂,双盲。
  • 主要终点为90天全因死亡率,分析基于意向性治疗人群。

关键数值与推荐

  • CAP合并脓毒性休克患者:氢化可的松50mg每6小时静脉推注联合氟氢可的松50μg每日鼻胃管给药,疗程7天。
  • 该方案可考虑用于CAP相关脓毒性休克,非CAP患者证据不支持常规使用。

临床怎么用

  • 对于社区获得性肺炎合并脓毒性休克的患者,可考虑使用氢化可的松联合氟氢可的松治疗以降低死亡率。
  • 非CAP相关脓毒性休克患者使用该方案未见显著获益,需个体化评估。
  • 治疗期间需监测严重不良事件,CAP患者中该方案严重不良事件风险较低。

局限性

  • 本分析为预设探索性亚组分析,检验效能不足以完全区分ARDS与CAP对皮质激素疗效的修饰作用。
  • 31例患者CAP状态无法判定,未纳入亚组分析。
  • 研究在法国34个中心进行,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucocorticoids probably improve outcomes in patients hospitalised for community acquired pneumonia (CAP). In this a priori planned exploratory subgroup analysis of the phase 3 randomised controlled Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, we aimed to investigate responses to hydrocortisone plus fludrocortisone between CAP and non-CAP related septic shock. METHODS: APROCCHSS was a randomised controlled trial that investigated the effects of hydrocortisone plus fludrocortisone, drotrecogin-alfa (activated), or both on mortality in septic shock in a two-by-two factorial design; after drotrecogin-alfa was withdrawn on October 2011, from the market, the trial continued on two parallel groups. It was conducted in 34 centres in France. In this subgroup study, patients with CAP were a preselected subgroup for an exploratory secondary analysis of the APROCCHSS trial of hydrocortisone plus fludrocortisone in septic shock. Adults with septic shock were randomised 1:1 to receive, in a double-blind manner, a 7-day treatment with daily administration of intravenous hydrocortisone 50 mg bolus every 6h and a tablet of 50 μg of fludrocortisone via the nasogastric tube, or their placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included all-cause mortality at intensive care unit (ICU) and hospital discharge, 28-day and 180-day mortality, the number of days alive and free of vasopressors, mechanical ventilation, or organ failure, and ICU and hospital free-days to 90-days. Analysis was done in the intention-to-treat population. The trial was registered at ClinicalTrials.gov (NCT00625209). FINDINGS: Of 1241 patients included in the APROCCHSS trial, CAP could not be ruled in or out in 31 patients, 562 had a diagnosis of CAP (279 in the placebo group and 283 in the corticosteroid group), and 648 patients did not have CAP (329 in the placebo group and 319 in the corticosteroid group). In patients with CAP, there were 109 (39%) deaths of 283 patients at day 90 with hydrocortisone plus fludrocortisone and 143 (51%) of 279 patients receiving placebo (odds ratio [OR] 0·60, 95% CI 0·43-0·83). In patients without CAP, there were 148 (46%) deaths of 319 patients at day 90 in the hydrocortisone and fludrocortisone group and 157 (48%) of 329 patients in the placebo group (OR 0·95, 95% CI 0·70-1·29). There was significant heterogeneity in corticosteroid effects on 90-day mortality across subgroups with CAP and without CAP (p=0·046 for both multiplicative and additive interaction tests; moderate credibility). Of 1241 patients included in the APROCCHSS trial, 648 (52%) had ARDS (328 in the placebo group and 320 in the corticosteroid group). There were 155 (48%) deaths of 320 patients at day 90 in the corticosteroid group and 186 (57%) of 328 patients in the placebo group. The OR for death at day 90 was 0·72 (95% CI 0·53-0·98) in patients with ARDS and 0·85 (0·61-1·20) in patients without ARDS (p=0·45 for multiplicative interaction and p=0·42 for additive interaction). The OR for observing at least one serious adverse event (corticosteroid group vs placebo) within 180 days post randomisation was 0·64 (95% CI 0·46-0·89) in the CAP subgroup and 1·02 (0·75-1·39) in the non-CAP subgroup (p=0·044 for multiplicative interaction and p=0·042 for additive interaction). INTERPRETATION: In a pre-specified subgroup analysis of the APROCCHSS trial of patients with CAP and septic shock, hydrocortisone plus fludrocortisone reduced mortality as compared with placebo. Although a large proportion of patients with CAP also met criteria for ARDS, the subgroup analysis was underpowered to fully discriminate between ARDS and CAP modifying effects on mortality reduction with corticosteroids. There was no evidence of a significant treatment effect of corticosteroids in the non-CAP subgroup. FUNDING: Programme Hospitalier de Recherche Clinique of the French Ministry of Health, by Programme d'Investissements d'Avenir, France 2030, and IAHU-ANR-0004.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Heming N, Renault A, Kuperminc E, et al. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial. Lancet Respir Med. 2024. PMID: 38310918. doi:10.1016/S2213-2600(23)00430-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。